| Expression pattern: |
DN |
| Associated gene: |
AGO2, XPA, XPC, Rad23B, RPA14, RPA32, RPA70, ERCC1 |
| Associated microRNA: |
hsa-miR-7-5p, hsa-miR-671-5p, hsa-miR-1270, hsa-miR-3156-5p |
| Biological function: |
Inhibits viability and proliferation, inhibits migration and invasion, promotes apoptosis, and increases cisplatin sensitivity in NSCLC cells. |
| Molecular mechanism: |
May function as a ceRNA by sponging four predicted miRNAs and modulating the nucleotide excision repair (NER) signaling pathway, thereby affecting cisplatin resistance/sensitivity. |
| Biological pathway or process: |
ceRNA regulation (other); drug resistance (inhibits); apoptosis (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; FISH / smFISH; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Colony Formation Assay; Wound Healing Assay; Transwell Assay; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; Luciferase Reporter Assay; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
May serve as a novel biomarker for diagnosis and prediction of platinum-based chemosensitivity in patients with NSCLC. |
| Description: |
hsa_circ_0001946 is down-regulated in NSCLC tissues and acts as a tumor suppressor in A549 cells. Its knockdown promotes proliferation/migration/invasion, reduces apoptosis, and increases cisplatin resistance by activating the NER pathway, potentially via a ceRNA mechanism involving miR-7-5p, miR-671-5p, miR-1270 and miR-3156-5p. |
| Confidence score: |
0.8355 |